-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Sensus Healthcare, Inc. (NASDAQ:SRTS) just released its second-quarter report and things are looking bullish. Statutory earnings performance was extremely strong, with revenue of US$12m beating expectations by 28% and earnings per share (EPS) of US$0.21, an impressive 65%ahead of expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
View our latest analysis for Sensus Healthcare
NasdaqGM:SRTS Earnings and Revenue Growth August 8th 2022Following the latest results, Sensus Healthcare's five analysts are now forecasting revenues of US$45.2m in 2022. This would be a solid 10% improvement in sales compared to the last 12 months. Statutory earnings per share are predicted to rise 2.2% to US$1.55. Before this earnings report, the analysts had been forecasting revenues of US$41.7m and earnings per share (EPS) of US$1.43 in 2022. So there seems to have been a moderate uplift in sentiment following the latest results, given the upgrades to both revenue and earnings per share forecasts for next year.
With these upgrades, we're not surprised to see that the analysts have lifted their price target 15% to US$16.50per share. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Sensus Healthcare, with the most bullish analyst valuing it at US$20.00 and the most bearish at US$14.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Sensus Healthcare's rate of growth is expected to accelerate meaningfully, with the forecast 22% annualised revenue growth to the end of 2022 noticeably faster than its historical growth of 3.6% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.8% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Sensus Healthcare to grow faster than the wider industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Sensus Healthcare following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Sensus Healthcare going out to 2024, and you can see them free on our platform here..
You should always think about risks though. Case in point, we've spotted 4 warning signs for Sensus Healthcare you should be aware of, and 1 of them is potentially serious.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
人口普查医疗保健公司。纳斯达克(Sequoia Capital:SRTS)刚刚发布了第二季度报告,情况看起来很乐观。法定收益表现极为强劲,营收1200万美元超出预期28%,每股收益(EPS)0.21美元,超出预期65%,令人印象深刻。分析师通常会在每一份收益报告中更新他们的预测,我们可以从他们的估计中判断他们对公司的看法是否发生了变化,或者是否有任何新的担忧需要注意。因此,我们收集了最新的盈利后法定共识估计,看看明年可能会发生什么。
查看我们对人口普查医疗保健的最新分析
NasdaqGM:SRTS收益和收入增长2022年8月8日根据最新的业绩,Scount Healthcare的五位分析师现在预测,2022年的收入将达到4520万美元。与过去12个月相比,这将是销售额稳步增长10%。预计法定每股收益将增长2.2%,至1.55美元。在这份收益报告之前,分析师一直预测2022年收入为4170万美元,每股收益(EPS)为1.43美元。因此,考虑到对明年营收和每股收益预期的上调,在最新业绩公布后,市场情绪似乎出现了温和的提振。
有了这些升级,我们并不惊讶地看到,分析师们将目标价上调了15%,至每股16.50美元。不过,还有另一种方式来考虑价格目标,那就是看看分析师提出的价格目标的范围,因为广泛的估计可能表明,对企业可能出现的结果有不同的看法。对Scount Healthcare有一些不同的看法,最乐观的分析师对其估值为20.00美元,最悲观的分析师估值为每股14.00美元。这表明,投资者的估值仍存在一定的差异性,但分析师似乎并不完全对该股持不同看法,好像这可能是一种成功或失败的局面。
当然,看待这些预测的另一种方式是将它们放在与行业本身相反的背景下。从最新的估计中可以清楚地看到,人口普查医疗保健的增长率预计将大幅加快,截至2022年底的年化收入增长预测为22%,明显快于历史上3.6%的年增长率。在过去的五年里。相比之下,同行业的其他公司预计每年收入增长7.8%。显然,尽管增长前景比最近的过去更光明,但分析师也预计人口普查医疗保健的增长速度将快于更广泛的行业。
底线
这里最重要的是,分析师上调了每股收益预期,表明在这些结果公布后,人们对人口普查医疗保健的乐观情绪明显增加。令人高兴的是,他们还上调了收入预期,他们的预测表明,该业务的增长速度预计将快于整个行业。目标价格也有了很大的提高,分析师们明显感觉到该业务的内在价值正在改善。
根据这一思路,我们认为,业务的长期前景比明年的收益更相关。在Simply Wall St.,我们有全方位的分析师对2024年人口普查医疗保健的预测,你可以在我们的平台上免费看到。
不过,你应该始终考虑风险。举个例子,我们发现人口普查医疗保健的4个警告信号您应该意识到,其中1个可能是严重的。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧